Sandoz outcomes: individuation improved safety

This episode accompanies Module 14 of the course, which is about evaluating the outcome of the decision we’ve taken or the solution we implemented. This is the last stage of our evidence-based management process and is vital to ensuring that we learn from what we’ve done.

Assessing outcomes is vital, because otherwise, how do we know if what we did was effective, and how can we learn and develop our approach to decision making?  Did we capture a baseline before the decision was implemented? And was the decision implemented as planned? If we assess outcomes without these two, then conclusions could be very suspect.

We continue our case study of the large trial at pharmaceutical organization Sandoz (part of Novartis Group), and find out how the D&I interventions were assessed.

Denise Rousseau's 2020 paper: Making Evidence based organisational decisions in an uncertain world 

After action review paper: https://www.cebma.org/wp-content/uploads/Guide-to-the-after_action_review.pdf 

Host: Karen Plum

 Guests:

• Eric Barends, Managing Director, Center for Evidence-Based Management 
• Denise Rousseau, H J Heinz University Professor, Carnegie Mellon University
• Stefanie Nickel, Global Head of Diversity & Inclusion, pharmaceutical manufacturer Sandoz, part of the Novartis Group

Additional speaker, courtesy of CIPD: Niamh McNamara, Global Head of People & Organisation, Novartis 

Find out more about the course here:   https://cebma.org/resources-and-tools/course-modules/